
Commentary|Videos|June 24, 2026
FDA Expands OTC Naloxone Access: What It Means for Patients and Pharmacists
Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about the FDA's expansion of over-the-counter naloxone access, remaining barriers to availability, and the critical role pharmacists play in overdose prevention and patient education.
Advertisement
Advertisement
Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about the FDA's expansion of over-the-counter naloxone access, remaining barriers to availability, and the critical role pharmacists play in overdose prevention and patient education.
Related to this article

Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.

Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.

The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.

Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.

Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.

Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.

Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
Advertisement
Advertisement

